Extracellular matrix (ECM) turnover plays an important role in left ventricular (LV) remodelling following myocardial infarction (MI). Cysteinyl cathepsins contribute to ECM catabolism in arterial diseases, suggesting their participation in post-MI remodelling.
Introduction
Left ventricular (LV) remodelling decisively determines clinical outcomes following myocardial infarction (MI). Adequate remodelling helps preserve cardiac function, while adverse remodelling portends a poor prognosis. Mechanisms influencing LV remodelling include inflammation, hemodynamic loading, neurohormonal activation, cytokine production, and extracellular responses such as fibrosis and protease-induced matrix breakdown.
Cardiac extracellular matrix (ECM) components include collagens (e.g. collagen types I and III), glycoproteins (e.g. fibronectin and laminins), proteoglycans, glycosaminoglycans, and matricellular proteins. Collagen types I and III, the most abundant cardiac ECM components, 1 form the scaffold for cardiomyocytes and thus, contribute to cardiac architecture and ventricular geometry. Fibronectin, although less abundant than interstitial collagens, has important functions such as chemoattractant activity for fibroblasts, endothelial cells (ECs), monocytes/ macrophages, 2 cellular adhesion, 3 and proinflammatory properties.
Fibronectin also regulates cardiac fibroblast trans-differentiation into myofibroblasts, 5, 6 the main cell types that produce collagen and fibronectin in the infracted myocardium. 7 Degradation and synthesis of myocardium matrix proteins both contribute to post-MI LV remodelling and cardiac function. Cysteinyl cathepsins contribute to arterial diseases by ECM degradation, promoting vascular cell apoptosis, and inducing angiogenesis. 8 Cathepsin K (CatK), cathepsin L (CatL), and cathepsin S (CatS) are potent proteases in degrading collagen and fibronectin 9, 10 -suggesting their participation in post-MI LV remodelling. We tested this hypothesis and explored the mechanisms by which these proteases might contribute to post-MI myocardial remodelling.
Methods
See Supplementary Material online.
Results

Cathepsin expression and activity in experimental mouse MI
Proteolytic activities of cysteinyl cathepsins in degrading collagen and fibronectin 9, 10 suggest that these proteases participate in post-MI cardiac remodelling. To test this hypothesis, we induced MI in C57BL/ 6 mice by ligating the left anterior descending (LAD) artery. Cardiac tissues from both infarcted and remote areas were collected at 1, 2, 3, 7, and 28 days post-MI. Cathepsin mRNA levels, as determined by realtime polymerase chain reaction (RT-PCR), were compared with those from sham-operated mouse hearts. CatS mRNA level induction was the highest in infarct tissues among tested cathepsin family members (including CatK, CatB, CatL, and their endogenous inhibitor, cystatin C). CatS expression peaked (.30-fold) at 7 days, and then decreased at 28 days post-MI ( Figure 1A ). CatB and CatS also rose in non-infarcted regions and peaked at 3 days, although at a much lower level than in infarct areas ( Figure 1B) . Measurement of active cathepsins yielded similar results, as shown by labelling infarct and remote tissue lysates with biotinylated-JPM, a probe that labels only active cathepsins.
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CatS and CatB activities peaked at 7 days post-MI in infarct areas, whereas CatB activities peaked at 3 days post-MI in remote areas ( Figure 1C) . Tissue lysate immunoblot analysis with anti-CatS polyclonal antibody 12 demonstrated a similar CatS expression pattern. Infarcted areas from 3 and 7 days post-MI contained higher CatS than other time points, whereas remote areas contained low levels of CatS protein ( Figure 1D ). Immunofluorescent staining of frozen cardiac sections prepared from 7-day post-MI mice demonstrated much higher CatS expression in infarct areas than in remote areas. Many troponin T-positive cardiomyocytes, vimentin-positive cardiac fibroblasts, and Mac-3-positive macrophages in infarct areas, but not in remote areas, expressed CatS (Supplementary material online, Figure S1A -C).
To examine whether increased CatS in the infarct area was also enzymatically active, we incubated infarct area tissue extracts (5 mg) with fluorescein-conjugated DQ elastin with and without 5 nM CatS-selective inhibitor morpholinurea-leucine-homophenylalaninevinylsulfone-phenyl (LHVS), to determine LHVS-inhibitable CatSspecific elastase activities by subtracting the optical density reading of reactions with LHVS from those without LHVS. 13 As in the JPM labelling in Figure 1C , infarct areas had the highest CatS elastase activities at 7 days post-MI ( Figure 1E ).
Pharmacological inhibition of cathepsins and post-MI cardiac functions
Increased expression and activity of cathepsins in post-MI myocardium suggest that these proteases participate in post-MI LV remodelling. To test this hypothesis, we administered a cell-permeable non-selective cathepsin inhibitor, E64d, by intraperitoneal injection to suppress the increased expression and activity of cathepsins. We did not use the CatS-selective inhibitor, LHVS, due to the lack of its commercial supply. Cathepsin activities increased 1 day post-MI ( Figure 1C) , and pre-incubating with a cathepsin inhibitor for a few hours is often necessary to yield complete inhibition of cathepsin activities in cultured cells. 14 We therefore injected 12.5 mg/kg/day E64d 15 12 h before LAD ligation to 7 days post-MI, to ensure sufficient inhibition of in vivo cathepsin activities by the concentration of E64d administered. E64d reduced CatS expression in cardiomyocytes, fibroblasts, and macrophages in infarct areas (Supplementary material online, Figure S1A -C, middle panels). Fluorescein-conjugated DQ elastin in situ zymography showed E64d-inhibitable elastase activity from 7-day post-MI cardiac frozen sections (Supplementary material online, Figure S2 , left two panels), and such activity was inhibited in mice that received E64d treatment (Supplementary material online, Figure S2 , right panel). Indices of LV function were assessed by echocardiography at baseline and at 7 and 28 days post-MI. Compared with the baselines, the LV end-diastolic diameter (EDD) and end-systolic diameter (ESD) increased significantly at 7 or 28 days post-MI in both vehicle-treated wild-type (WT) control mice and those receiving intraperitoneal E64d (Figure 2A Figure 2C ), likely due to the baseline LV EDD and LV ESD differences between the groups. E64d administration also impaired ejection fraction (EF) and fractional shortening (FS; Figure 2D ), suggesting that both post-MI systolic and diastolic functions were further impaired after cathepsin inhibition. E64d did not, however, affect infarct sizes in C57BL/6 mice at 7 and 28 days post-MI (Supplementary material online, Figure S3 ), as calculated by the percentage of infarct length in total LV circumference at the mid-papillary-muscle level-suggesting that E64d did not affect cardiomyocyte apoptosis, a causal factor of infarct, and heart failure. 16, 17 Among sham-operated mice, E64d did not affect LV EDD, LV ESD, or percentages of EF and FS at baseline and at 7 or 28 days after sham operation (Supplementary material online, Figure S4 ).
Cathepsin inhibition alters LV inflammation and collagen expression
Inflammation and fibrosis regulate post-MI scar formation and remodelling. 18 MI patients have lower CD4 + /CD8 + ratios than control. 19 Immunostaining revealed increased CD4 + and CD8 + T-cells in the infarct border zone 7 days post-MI, compared with those from sham-operated mice. E64d treatment significantly reduced infarct border zone CD4 + T-cells, but concurrently increased CD8 + T-cells ( Figure 3A and Supplementary material online, Figure S5 ), leading to even lower CD4 + /CD8 + T-cell ratios than in the vehicle control group. Similarly, E64d accentuated the accumulation of macrophages (Mac3 + ) and the major histocompatibility complex (MHC) class-II-positive cells in the infarcted myocardium areas ( Figure 3A and Supplementary material online, Figure S5 ), suggesting that cathepsin inhibition enhanced post-MI inflammation. Both T-cells and macrophages produce proinflammatory cytokines and chemokines that influence post-MI LV remodelling.
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E64d treatment increased post-MI expression of interleukin (IL)-1b, IL-6, tumour necrosis factor-a, interferon-g, and monocyte chemoattractant protein-1 (MCP-1) as determined by RT-PCR (Supplementary material online, Figure S6 ), consistent with enhanced inflammation after cathepsin inhibition. As several cathepsins-including CatK, CatL, and CatB-show collagenase activity, impaired LV function in mice receiving E64d may be partially due to altered collagen degradation or synthesis. To test this possibility, we performed immunostaining to detect areas positive for collagen types I and III in the infarct and remote myocardium.
At 7 days post-MI, E64d increased collagen type I-positive areas in infarct areas, but not in remote areas. At 28 days post-MI, however, cathepsin inhibition showed lower type I collagen content than vehicle control ( Figure 3B ). In contrast, collagen type III increased in both infarct and remote areas at 28 days post-MI ( Figure 3C ). These observations suggest that increased cathepsin collagenase activities contributed to collagen I turnover at 7 days post-MI. Such activities were less important at later time points, when cathepsin activities decreased to the level of baseline ( Figure 1C and E). At 28 days post-MI, E64d-controlled collagen synthesis may become dominant in regulating myocardium collagen deposition. E64d administration blunted the increase of the collagen type I/III ratio in the infarct zone at 28 days post-MI. The collagen type Figure 1 Mouse heart tissue protease expression and activities. Quantitative RT-PCR determined cathepsin mRNA levels in infarct areas (A) and remote areas (B) at 1, 2, 3, 7, and 28 days post-MI. mRNA levels were normalized to b-actin. Data from each group were compared with those from sham-operated mice. Data were representative of three independent experiments. (C) JPM labelling assessed cathepsin activities in lysates from infarct and remote areas from sham-operated mice and at 1, 2, 3, 7, and 28 days post-MI. A representative JPM labelling gel is presented on the left. Data are mean + SEM of four sets of independent samples. A P-value of ,0.05 was considered statistically significant, compared with the day 0 time point. (D) Immunoblot analysis to detect CatS from infarct and remote hearts. GAPDH was used as protein loading control. (E) Infarct area tissue extracts from WT mice (n ¼ 6 -13) at indicated days post-MI were used for elastase assay, with and without LHVS, to detect LHVS-inhibitable CatS elastase activities. Infarct area tissue extracts from Ctss -/ -mice at 0 and 7 days post-MI were used as negative controls.
I/III ratio in remote areas also fell significantly in E64d-treated mice, compared with that in vehicle-treated mice at 28 days post-MI ( Figure 3D ). An increased collagen type I/III ratio in both infarcted and remote areas after E64d treatment at 7 days post-MI may increase cardiac stiffness, 21 thereby impairing cardiac function ( Figure 2) . Moreover, the reduced collagen type I/III ratio at 28 days post-MI did not explain sustained impairment in cardiac function in E64d-treated animals. This observation may thus involve the operation of mechanisms other than collagen deposition. Cysteinyl cathepsins contribute to cardiac cell apoptosis and angiogenesis. 8, 22 TUNEL staining and CD31 immunostaining revealed that E64d treatment did not significantly alter apoptosis or angiogenesis, compared with those treated with vehicle control (Supplementary material online, Figure S7 ), consistent with observations that E64 did not significantly affect infarct sizes at 7 and 28 days post-MI (Supplementary material online, Figure S3 ). The role of cathepsins in myocardial apoptosis and angiogenesis therefore do not explain impaired heart functions in E64d-treated mice.
Cathepsin inhibition and fibroblast trans-differentiation
Upon ischaemic injury, fibroblasts may acquire characteristics of myofibroblasts and express smooth muscle actin (a-SMA) and vimentin, a process denoted 'trans-differentiation'. 7 TGF-b1 promotes this process. 23 Immunostaining of heart frozen sections from 7 days post-MI with a-SMA antibody showed a significant increase of a-SMA-positive cells outside the vascular wall after MI, compared with sham-operated mice. E64d greatly reduced the numbers of a-SMA-positive myofibroblasts ( Figure 4A and Supplementary material online, Figure S8 ). Fibronectin provides structural support and cell adhesion to the myocardium 24 and promotes fibroblast trans-differentiation into myofibroblasts. 6 Fibronectin alternative RNA splicing yields the cellular fragments extra domain A (ED-A). By binding to a receptor (as yet not fully defined), ED-A mediates TGF-b1-triggered deposition of a-SMA and collagen type I. 6 Reduced a-SMA-positive myofibroblasts in infarct areas from E64d-treated mice ( Figure 4A ) suggest that cathepsins foster fibroblast transformation via the generation of ED-A fragments.
Immunostaining and immunoblot analysis of cardiac tissues from infarct areas demonstrated concurrent increases of fibronectin and a-SMA at 7 days post-MI, compared with remote areas. E64d suppressed the expression of both a-SMA and fibronectin ( Figure 4A and B, and Supplementary material online, Figure S8 ), suggesting that cathepsins favour fibroblast trans-differentiation. To explore this hypothesis further, we performed immunostaining and immunoblot analysis to detect ED-A in infarct tissues from 7 days post-MI. E64d suppressed the expression of this fibronectin variant in infarcted hearts ( Figure 4A and C, and Supplementary material online, Figure S8 ). Reduced fibronectin ED-A expression and myofibroblast transdifferentiation by E64d may result not only from the inhibition of cathepsin activity, but also the expression of cysteinyl cathepsins and possibly other proteases, such as matrix metalloproteinases (MMPs). We performed RT-PCR, CatS immunoblot analysis, cathepsin active site labelling with biotinylated-JPM, and MMP gelatin gel zymography to test these possibilities. RT-PCR demonstrated that E64d reduced the expression of most cathepsins tested, including CatB, CatS, CatL, and cystatin C, in infarct zones but not those in remote regions (Supplementary material online, Figure S9A and B) . CatS immunoblot analysis and cathepsin active site labelling with JPM showed that MI increased the expression and activities of CatB and CatS ( Figures 1C and 4C and D) . E64d inhibited their expression and activities in infarct zones to a greater extent than in remote regions-likely due to overall low cathepsin activities in the non-infarcted myocardium ( Figure 4D and Supplementary material online, Figure S9B ). Gelatin gel zymography showed that E64d did not reduce MMP-2 and -9 activities in either infarct or remote regions (Supplementary material online, Figure S9C) .
CatS increased more than other cathepsins at the RNA level ( Figure 1A) , and E64d fully inhibited its expression and activity ( Figure 4C and D) in infarct zones. Reduced ED-A ( Figure 4A and C and Supplementary material online, Figure S8 ), impaired myofibroblast trans-differentiation ( Figure 4A and B) , and cardiac function (Figure 2 ) after E64d treatment may result from CatS inhibition. Immunostaining demonstrated increased CatS expression, which was colocalized to cardiomyocytes, cardiac fibroblasts, and infiltrated macrophages (Supplementary material online, Figure S1 ), in infarct areas at 7 days post-MI, compared with those in sham-operated cardiac tissues (Supplementary material online, Figure S10A and B). E64d reduced CatS protein and mRNA levels in infarct zones ( Figure 4C and D and Supplementary material online, Figures S1, S9A , and S10C), although CatS expression in remote regions was too low to be detected by immunostaining (Supplementary material online, Figure S10B ) or active site labelling ( Figure 4D) . 
CatS and myofibroblast trans-differentiation in vitro
Mechanical tension, TGF-b1, and the fibronectin ED-A variant are wellidentified mediators of cardiac fibroblast trans-differentiation. Consistent with a role of CatS in myofibroblast trans-differentiation, TGF-b1 concurrently augmented the expression of CatS and a-SMA in fibroblasts in both time-dependent and dose-dependent manners, as determined by RT-PCR ( Figure 5A and B) and immunoblot analysis ( Figure 5C )-suggesting that CatS participates in myofibroblast transdifferentiation. To test this hypothesis further, we exposed fibroblasts from WT and Ctss -/ -mice to TGF-b1. At all concentrations tested, TGF-b1 induced a-SMA expression in fibroblasts from WT mice to a much greater extent than in those from Ctss -/ -mice ( Figure 5D ), suggesting a critical role of CatS in TGF-b1-induced myofibroblast transdifferentiation. Reduced a-SMA expression in infarcted hearts from E64d-treated mice ( Figure 4A and B and Supplementary material online, Figure S8 ) thus results at least in part from inhibited CatS activity. To examine this hypothesis in vitro, we treated fibroblasts with 10 ng/mL of TGF-b1, with or without 20 mM E64d, and 5 nM of the CatS-selective inhibitor LHVS. 13 After 24 h of incubation, E64d and LHVS showed comparable inhibition on TGF-b1-induced CatS and a-SMA expression in fibroblast at mRNA levels, as determined by RT-PCR ( Figure 5E and F ). Immunoblot analysis showed that E64d also suppressed the expression of both a-SMA and fibronectin. CatS deficiency showed a similar inhibitory effect, though milder than that of E64d ( Figure 5G ). These observations suggest that TGF-b1-induced myofibroblast transdifferentiation is CatS-dependent. Why inhibition of cathepsins by E64d or LHVS reduced the expression of a-SMA and fibronectin, or even CatS in isolated cardiac fibroblasts ( Figure 5E -G) and in the myocardium ( Figure 4 and Supplementary material online, Figure S1 , middle panels; Supplementary material online, Figures S8 and S10) , is not fully understood. The role of CatS in myofibroblast trans-differentiation is probably only one of the mechanisms. Other unexplained mechanisms may also contribute to E64d-reduced protease or matrix protein expression independent of myofibroblast trans-differentiation. 25 ,26
CatS deficiency aggravates post-MI LV dilation and functional impairment
We performed LAD ligation in Ctss -/ -mice to test directly whether the absence of CatS accentuates LV dilation and deterioration in cardiac function, as in E64d-treated mice. Survival rates up to 28 days post-MI were similar between Ctss -/ -mice and those receiving daily E64d for 1 week ( 80%), and both showed no statistical significance in mortality from WT mice or those receiving vehicle treatment (Supplementary material online, Figure S11A and B). Moreover, Ctss -/ -mice showed significantly impaired post-MI cardiac function, compared with WT mice. At 7 days post-MI, Ctss -/ -mice had greater increases in LV EDD and LV ESD than did WT mice. At 28 days post-MI, LV ESD remained significantly larger in Ctss -/ -than in WT mice ( Figure 6A and B). At both time points, Ctss -/ -mice had significantly reduced %ES and EF, compared with WT mice ( Figure 6B ). These observations support the hypothesis that E64d-reduced LV function post-MI results at least in part from CatS inhibition.
CatS deficiency and post-MI cardiac matrix protein expression and myofibroblast trans-differentiation
Similar impairment in cardiac function in both Ctss -/ -mice and those receiving E64d suggest that CatS contributes to post-MI remodelling by preventing myofibroblast trans-differentiation and regulating collagen deposition and fibronectin expression, which lead to increased myocardium stiffness and impaired cardiac function. Cathepsin active site Cysteinyl cathepsins in myocardial infarction labelling using biotinylated-JPM analysis revealed that CatS deficiency depleted CatS activity in cardiac tissue extracts from infarct regions, compared with WT mice ( Figure 7A ). The remaining JPM-binding material in Ctss -/ -mouse infarct regions likely represents CatK, which has the same molecular weight as CatS. 11, 27 Areas remote from the MI did not contain CatS activity as detected by JPM binding (data not shown). Similar to that in E64d-treated mice at 28 days post-MI ( Figure 3D ), the collagen type I/III ratio fell significantly in Ctss -/ -mice due to the significantly increased collagen type III deposition in infarct areas, although the absence of CatS did not affect collagen type I deposition ( Figure 7B ). In addition, infarcts in Ctss -/ -mice showed significantly reduced numbers of a-SMA-positive cells, compared with those from WT mice ( Figure 7C and Supplementary material online, Figure S12 )-supporting a critical role of CatS in regulating myofibroblast transdifferentiation. As in E64d-treated mice, increased expressions of fibronectin, a-SMA, and ED-A in infarct zones were significantly reduced in Ctss -/ -than in WT mice ( Figure 7D ).
TGF-b1 induces the expression of CatS, a-SMA ( Figure 5A-C) , fibronectin, 28 and collagen. 29 TGF-b1 signalling involves the activation of Smad2, Smad3, and Smad4 30 -transcription factors activated in myocardium post-MI. 31 In mouse MI, Smad3 deficiency 32 suppressed chemokine expression and collagen deposition in the infarcted myocardium, without affecting infarct size-which is congruent with our observations in E64d-treated and Ctss -/ -mice. In isolated cardiac fibroblasts, Smad3 deficiency abrogated procollagen type III expression and profibrotic TGF-b1 responses. 29 We therefore hypothesized that cathepsins control myocardium ECM protein expression (collagen and fibronectin) and myofibroblast trans-differentiation by regulating TGF-b1-induced Smad activation. Immunoblot analysis demonstrated that TGF-b1 induced phosphorylation of both Smad2 and Smad3 in cardiac fibroblasts from WT mice, but such phosphorylation was suppressed in those from Ctss -/ -mice ( Figure 7E ). Immunostaining with anti-phospho-Smad2 and phospho-Smad3 polyclonal antibodies also detected Smad2 and Smad3 phosphorylation and accumulation to the nuclei in 7-day post-MI myocardium. E64d administration or CatS deficiency significantly diminished Smad2 and Smad3 phosphorylation (Supplementary material online, Figure S13A and B). In contrast, cathepsin inhibition with E64d or CatS deficiency did not significantly affect MAPK activation. Immunostaining with an anti-mouse phopho-ERK1/2 (extracellular signal-regulated kinase) polyclonal antibody revealed negligible signals in sham-operated heart sections from WT and Ctss -/ -mice (Supplementary material online, Figure S14A ), but increased expression and nuclear accumulation of phospho-ERK 7 days post-MI in heart sections from WT mice, WT mice with E64d, and Ctss -/ -mice (Supplementary material online, Figure S14B -E) without significant differences (Supplementary material online, Figure S14F ). These observations conform with the non-significant differences in cardiac cell death in 7-day post-MI hearts from WT mice that received vehicle and E64d (Supplementary material online, Figure S7 , left panel).
Discussion
Post-MI LV remodelling involves inflammatory cell infiltration, cardiac cell apoptosis, angiogenesis, and matrix protein synthesis and degradation. Mechanical tension, TGF-b1, or ED-A fibronectin induce cardiac fibroblasts trans-differentiate into myofibroblasts, predominant cell types that synthesize ECM proteins to ensure scar stability, and provide contractile action to preserve cardiac function. Impaired synthesis or excessive breakdown of ECM proteins can aggravate post-MI cardiac dysfunction. This study established a novel role of CatS in TGF-b1 signalling, myofibroblast trans-differentiation, and ECM production, such as collagen, fibronectin, and ED-A, all which are essential to post-MI cardiac remodelling. Among all cathepsins, CatL has been studied in mouse MI; CatLdeficient (Ctsl -/ -) mice demonstrated larger infarcts, increased LV diameters, thinner infarct segment thickness, and decreased cardiac function, compared with those in Ctsl +/+ mice. 33 Moreover, inhibition of CatL activity does not explain our observations in E64d-treated mice. After MI, the mortality rate in Ctsl -/ -mice was 45 vs. 20% in E64d-treated mice (Supplementary material online, Figure S11 ). CatL deficiency decreased myocardial MMP activities, reduced inflammatory cells (c-kit-positive cells and macrophages) in both peripheral blood and myocardium, and inhibited infarct border zone EC proliferation and neovascularization, although the same deficiency also reduced infarct myofibroblast proliferation and a-SMA production. Inhibition of CatL activity therefore cannot explain the effects of E64d on post-MI LV remodelling and heart functions observed in our study. In the myocardium, CatB accounts for most of the cysteinyl cathepsin activity in both infarct and remote zones ( Figure 1C) , and E64d inhibited its activity ( Figure 4D) . We lack evidence, however, for the role of CatB in E64d-induced adverse effects on cardiac function, as proposed in Figure 2 . Fewer than 20% of mice survive 3 days after experimental MI, rendering the study of CatB contribution technically difficult (data not shown). Further, CatB activities did not differ between WT and Ctss -/ -mice in infarcted ( Figure 7A ) and remote areas, but these mice demonstrated clear differences in cardiac function ( Figure 6A and B), ECM expression ( Figure 7B-D) , TGF-b1 signalling ( Figure 7E and Supplementary material online, Figure S13 ), and fibroblast trans-differentiation ( Figure 7C and D and Supplementary material online, Figure S12 ). The way these variables differed between WT and Ctss -/ -mice resembled that between WT and E64d-treated WT mice. CatS therefore may be the main target of E64d in the infarcted myocardium.
In non-MI mice, most of the cells in the myocardium from Ctsl -/ -mice contain multiple large and fused lysosomes, characterized by the accumulation of large amounts of electron-dense heterogeneous materials with significantly increased myocardium collagen deposition, interstitial fibrosis, and ventricular and atrial enlargement. CatL deficiency increases intracellular dysmorphic and acidic organelles, which are accompanied by biochemical and mitochondrial impairment-all of which may associate with later development in cardiomyopathy. 34, 35 In contrast, none of these phenotypes have been observed or reported in Ctss -/ -mice, suggesting that CatS participates in post-MI cardiac remodelling using a different mechanism than that of CatL. CatS is one of the main cathepsins involving fibronectin ED-A expression. Although our observations do not establish that CatS inhibition alone accounts for accentuated LV remodelling in E64d-treated mice, CatS certainly participates in post-MI myocardial fibronectin ED-A expression and myofibroblast trans-differentiation. In addition to the similar mortality rate between Ctss -/ -mice and those receiving E64d (Supplementary material online, Figure S11 ), CatS deficiency yielded effects similar to those of E64d treatment on fibronectin ED-A and myofibroblast a-SMA expression ( Figures 4A-C and 7C and D) , which led to impaired LV remodelling and function (Figures 2 and 6 ). Many cathepsins, 36 including CatS, 10 degrade fibronectin. We lack evidence that cathepsin-mediated proteolysis of fibronectin contributes to post-MI LV remodelling, because both full-length fibronectin and spliced fibronectin (ED-A) levels were reduced in the absence of CatS ( Figure 7D ) or after inhibition of all cysteinyl cathepsins ( Figure 4B and C ). The effects of cathepsins on ECM expression therefore influence post-MI LV remodelling, while their participation in ECM catabolism may be less important than in other diseases, such as cancers or arterial diseases, including atherosclerosis and abdominal aortic aneurysms.
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Proinflammatory macrophages and T-cells express high levels of cathepsins, 11, 37 and these cells increased in the hearts of E64d-treated mice ( Figure 3A and Supplementary material online, Figure S5 ), suggesting that the reduced cardiac cathepsin expression and activities did not result solely from increased infiltration of proinflammatory cells. Cardiomyocytes and fibroblasts in the infarcted myocardium also express CatS (Supplementary material online, Figure S1 ). In mice, the effects of E64d on cathepsin expression in the infarcted myocardium paralleled changes in a-SMA, fibronectin, and ED-A ( Figure 4B -D and Supplementary material online, Figures S1 and 7A) . In vitro, TGF-b1 induced coordinate expression of CatS and a-SMA in cardiac fibroblasts ( Figure 5A-C) . Fibroblasts in infarcted hearts therefore may be an important source of cathepsins. Unlike cathepsins from leukocytes, which often catabolize ECM, 11, 18, 19 cathepsins in fibroblasts might participate less in ECM proteolysis, but rather act intracellularly to modulate fibroblast trans-differentiation into a-SMA-positive myofibroblasts, which produce cardiac collagens and fibronectins. 7 TGF-b1 mediates fibroblast trans-differentiation via the Smad2/Smad3 pathway. 30 Such activity of TGF-b1 was reduced in fibroblasts isolated from Ctss -/ -mice ( Figure 7E) , suggesting a role of CatS in TGF-b1-mediated Smad2/ Smad3 signalling, but how CatS affects this signalling pathway remains unknown. In this study, we demonstrated that CatS deficiency or total cathepsin inhibition by E64d limited the activation of Smad2/Smad3 signalling molecules in the border of infarcted hearts to a much greater extent than that from recombinant TGF-b1-activated cardiac fibroblasts in vitro (Supplementary material online, Figure S13 ). These observations are consistent with reduced expression or immunolocalization of a-SMA and ED-A in mouse post-MI myocardium (Figures 4A-C and Gel density ratios relative to GAPDH were shown to the right. (E) Immunoblot analysis of TGF-b1 induced p-Smad2 and p-Smad3 in cardiac fibroblasts from WT and Ctss -/ -mice. The same blot was reprobed for GAPDH to ensure equal protein loading.
7C and D; Supplementary material online, Figures S8 and S12) , but suggest that, in addition to targeting TGF-b1 signalling molecules directly ( Figure 7E ), cathepsins also participate in TGF-b1 expression or activation. This hypothesis has been tested in several prior studies. In hepatic stellate cells, increased CatB activity enhanced TGF-b1 expression, and CatB selective inhibitor (Ca074me) reduced the expression of a-SMA and TGF-b1. 38, 39 Both recombinant CatB and the enzyme from
Leishmania parasites cleave latent TGF-b1 into its active form. 40 In the current study, cathepsin inhibition with E64d and CatS deficiency also may have reduced TGF-b1 expression or activation-an alternative explanation for impaired Smad2/Smad3 activation (Supplementary material online, Figure S13 ). This study revealed that cysteinyl cathepsins participate importantly in post-MI LV remodelling. These proteases not only mediate ECM degradation, but also regulate TGF-b1 signalling, myofibroblast transdifferentiation, and myocardium ECM protein (e.g. collagen, fibronectin, ED-A) expression. Cathepsins therefore may contribute directly to cardiac rupture/stability in human MI. Of note, several cathepsin inhibitors are undergoing clinical trials for autoimmune and possibly vascular diseases; reconsidering the safety of cathepsin inhibitors among patients with acute MI and associated complications is vitally important. Further studies might be necessary to estimate the time window of cathepsin inhibition against post-MI LV remodelling.
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